Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker SLN
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Raymond Debbane | 8.66M | 4.6% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Ulys, L.L.C. | 1.07M | 0.6% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Avicenna Life Sci Master GP LLC | 1.07M | 0.6% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Avicenna Life Sci Master Fund LP | 1.07M | 0.6% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Siren, L.L.C. | 7.59M | 4.1% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Invus Global Management, LLC | 7.59M | 4.1% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Invus Public Equities Advisors, LLC | 7.59M | 4.1% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Invus Public Equities, L.P. | 7.59M | 4.1% | SCHEDULE 13G/A ↗ |
| Nov 5, 2026 | SCHEDULE 13G | SLN Silence Therapeutics Plc | Abigail P. Johnson | 13.18M | 7.1% | SCHEDULE 13G ↗ |
| Nov 5, 2026 | SCHEDULE 13G | SLN Silence Therapeutics Plc | FMR LLC | 13.18M | 7.1% | SCHEDULE 13G ↗ |
| Oct 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Reade E. Griffith | 9.88M | 5.3% | SCHEDULE 13G/A ↗ |
| Oct 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Patrick G. G. Dear | 9.88M | 5.3% | SCHEDULE 13G/A ↗ |
| Oct 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Tetragon Financial Management LP | 9.88M | 5.3% | SCHEDULE 13G/A ↗ |
| Oct 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Tetragon Financial Group Limited | 9.88M | 5.3% | SCHEDULE 13G/A ↗ |
| Oct 13, 2026 | SCHEDULE 13G | SLN Silence Therapeutics Plc | Reade E. Griffith | 9.71M | 5.2% | SCHEDULE 13G ↗ |
| Oct 13, 2026 | SCHEDULE 13G | SLN Silence Therapeutics Plc | Patrick G. G. Dear | 9.71M | 5.2% | SCHEDULE 13G ↗ |
| Oct 13, 2026 | SCHEDULE 13G | SLN Silence Therapeutics Plc | Tetragon Financial Management LP | 9.71M | 5.2% | SCHEDULE 13G ↗ |
| Oct 13, 2026 | SCHEDULE 13G | SLN Silence Therapeutics Plc | Tetragon Financial Group Limited | 9.71M | 5.2% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Raymond Debbane | 9.93M | 7.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Ulys, L.L.C. | 1.23M | 0.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Avicenna Life Sci Master GP LLC | 1.23M | 0.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Avicenna Life Sci Master Fund LP | 1.23M | 0.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Siren, L.L.C. | 8.71M | 6.1% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Invus Global Management, LLC | 8.71M | 6.1% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Invus Public Equities Advisors, LLC | 8.71M | 6.1% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Invus Public Equities, L.P. | 8.71M | 6.1% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Richard Griffiths | 14.39M | 8.0% | SCHEDULE 13D/A ↗ |
| Jul 8, 2026 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Ora Capital Limited | 19.16M | 13.5% | SCHEDULE 13D/A ↗ |
| Jul 8, 2026 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Richard Griffiths | 30.84M | 21.7% | SCHEDULE 13D/A ↗ |
| Feb 9, 2026 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Lombard Odier Asset Management (USA) Corp | 5.94M | 4.2% | SCHEDULE 13G/A ↗ |
| Jun 25, 2025 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Ora Capital Limited | 19.22M | 13.6% | SCHEDULE 13D/A ↗ |
| Jun 25, 2025 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Richard Ian Griffiths | 34.54M | 24.4% | SCHEDULE 13D/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Jeremy C. Green | 6.64M | 4.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Redmile Group, LLC | 6.64M | 4.7% | SCHEDULE 13G/A ↗ |
| May 8, 2025 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Ora Capital Limited | 19.22M | 13.6% | SCHEDULE 13D/A ↗ |
| May 8, 2025 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Richard Ian Griffiths | 32.91M | 23.2% | SCHEDULE 13D/A ↗ |
| Apr 24, 2025 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Ora Capital Limited | 19.22M | 13.6% | SCHEDULE 13D/A ↗ |
| Apr 24, 2025 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Richard Ian Griffiths | 30.93M | 21.8% | SCHEDULE 13D/A ↗ |
| Mar 31, 2025 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Ora Capital Limited | 19.22M | 13.6% | SCHEDULE 13D/A ↗ |
| Mar 31, 2025 | SCHEDULE 13D/A (amended) | SLN Silence Therapeutics Plc | Richard Ian Griffiths | 29.28M | 20.7% | SCHEDULE 13D/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G | SLN Silence Therapeutics Plc | Jeremy C. Green | 7.20M | 5.1% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | SLN Silence Therapeutics Plc | Redmile Group, LLC | 7.20M | 5.1% | SCHEDULE 13G ↗ |
| Feb 11, 2025 | SCHEDULE 13G/A (amended) | SLN Silence Therapeutics Plc | Lombard Odier Asset Management (USA) Corp | 10.71M | 7.6% | SCHEDULE 13G/A ↗ |
43 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances